Akebia Therapeutics (AKBA) Tops Q2 EPS by 1c
Tweet
Share
E-mailGet Alerts AKBA Hot Sheet
Join SI Premium – FREE
Akebia Therapeutics (NASDAQ: AKBA) reported Q2 EPS of ($0.03), $0.01 better than the analyst estimate of ($0.04). Revenue for the quarter came in at $49 million versus the consensus estimate of $50.93 million.
For earnings history and earnings-related data on Akebia Therapeutics (AKBA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Paramount Weighs Tapping Musk For Equity Investment - Semafor
- Cintas Corp. (CTAS) Tops Q1 EPS by 1c, Offers Guidance
- Canaccord Reiterates Buy Rating on Hammond Power Solutions (HPS-A:CN)
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
